We are proud to announce that Emily’s Entourage has provided seed funding to launch Talee Bio, a novel gene therapy company focused on developing revolutionary treatments and a cure for Cystic Fibrosis (CF).
The mission at Talee Bio is to change the game in Cystic Fibrosis by using “gene therapy technologies…designed to overcome the barriers that have so far prevented effective genetic treatments for cystic fibrosis,” according to their website.
Currently, the company is advancing two gene therapy programs originating from the company’s academic founders at the University of Iowa.
Among the most exciting elements of the program is that, unlike many of the targeted therapies in market and development for CF treatment, these gene therapy approaches could go far beyond merely controlling the disease–they could cure the disease.
In addition, these gene therapies are “mutation-agnostic,” meaning they would treat everyone with CF no matter the individual’s genetic mutation.
The work reflects over 100 years of collective experience on behalf of the academic founders at the University of Iowa and Children’s Hospital of Philadelphia, who are among the most preeminent researchers in the fields of CF, pathophysiology, and gene therapy.
Talee Bio represents a unique partnership between the University of Iowa, Children’s Hospital of Philadelphia and Philadelphia venture firm Militia Hill Ventures. The company was made possible through the seed funding, scientific connections, and impetus provided by Emily’s Entourage.
In fact, the name “Talee” reflects its origin. “Tal” comes from Emily’s Hebrew name Talia, which implies life, and “ee” comes from the Entourage that made it all possible.
The partnership is a powerful example of venture philanthropy, where a percentage of Talee product sales are returned to Emily’s Entourage to be reinvested into research and propel future breakthroughs. In a race against the clock, this venture philanthropy model can expedite advances by harnessing the power of venture capital.